Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 18Gastrointestinal 12Gynecologic 6Tumor-Agnostic 4Thoracic 3Sarcoma 3CNS 3Head & Neck 2Genitourinary 2Dermatologic 1

Conditions

Salivary Gland Neoplasms 2Endometrial Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Melanoma 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Cisplatin 47pembrolizumab 37Magnetic Resonance Spectroscopy 33Specimen Handling 27Radiotherapy, Intensity-Modulated 21Cetuximab 19Nivolumab 18Carboplatin 16Platinum 151,2-diaminocyclohexaneplatinum II citrate 15Radiotherapy 14Biopsy 12Paclitaxel 11Gemcitabine 10Docetaxel 10Surveys and Questionnaires 9Radiation 9Immunoglobulin G 7Disulfides 7toripalimab 6cemiplimab 6Ipilimumab 6Fluorouracil 6Bevacizumab 6dostarlimab 5atezolizumab 5Watchful Waiting 5Taxes 5Immune Checkpoint Inhibitors 5Drug Therapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
trastuzumab deruxtecan × Head & Neck × 30 days × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡